Anti-HLA antibodies in regenerative medicine stem cell therapy

Human Immunology

Volumn 73, Issue 12, 2012, Pages 1287-1294

  Charron, Dominique ^a   Suberbielle Boissel, Caroline ^a   Tamouza, Ryad ^a   Al Daccak, Reem ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY;

ARTICLE; CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

ANTIBODIES; GENE EXPRESSION REGULATION; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; REGENERATIVE MEDICINE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84869082154     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.06.010     Document Type: Article

References (82)

1. Ebben J.D., Zorniak M., Clark P.A., Kuo J.S. Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine. World Neurosurg 2011, 76:270.
2. Evans M. Discovering pluripotency: 30 years of mouse embryonic stem cells. Nat Rev Mol Cell Biol 2011, 12:680.
3. Mohsin S., Siddiqi S., Collins B., Sussman M.A. Empowering adult stem cells for myocardial regeneration. Circ Res 2011, 109:1415.
4. Borlongan C.V., Glover L.E., Tajiri N., Kaneko Y., Freeman T.B. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol 2011, 95:213.
5. Drukker M., Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004, 22:136.
6. Drukker M., Katchman H., Katz G., Even-Tov Friedman S., Shezen E., Hornstein E., et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2006, 24:221.
7. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212.
8. Kofidis T., DeBruin J.L., Tanaka M., Zwierzchoniewska M., Weissman I., Fedoseyeva E., et al. They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur J Cardiothorac Surg 2005, 28:461.
9. Swijnenburg R.J., Tanaka M., Vogel H., Baker J., Kofidis T., Gunawan F., et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005, 112:I166.
10. Charron D., Suberbielle-Boissel C., Al-Daccak R. Immunogenicity and allogenicity: a challenge of stem cell therapy. J Cardiovasc Transl Res 2009, 2:130.
11. Dhodapkar K.M., Feldman D., Matthews P., Radfar S., Pickering R., Turkula S., et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010, 107:8718.
12. Drukker M., Katz G., Urbach A., Schuldiner M., Markel G., Itskovitz-Eldor J., et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002, 99:9864.
13. Tarte K., Gaillard J., Lataillade J.J., Fouillard L., Becker M., Mossafa H., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115:1549.
14. Bocelli-Tyndall C., Zajac P., Di Maggio N., Trella E., Benvenuto F., Iezzi G., et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010, 62:3815.
15. Erlich H.A., Opelz G., Hansen J. HLA DNA typing and transplantation. Immunity 2001, 14:347.
16. Li F., Atz M.E., Reed E.F. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009, 21:557.
17. Clatworthy M.R., Espeli M., Torpey N., Smith K.G. The generation and maintenance of serum alloantibody. Curr Opin Immunol 2010, 22:669.
18. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004, 4:438.
19. Reed E.F., Demetris A.J., Hammond E., Itescu S., Kobashigawa J.A., Reinsmoen N.L., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006, 25:153.
20. Valenzuela N.M., Reed E.F. The link between major histocompatibility complex antibodies and cell proliferation. Transplant Rev (Orlando) 2011, 25:154.
21. Al-Daccak R., Mooney N., Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 2004, 16:108.
22. Wu D.C., Boyd A.S., Wood K.J. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 2008, 26:1939.
23. Poncelet A.J., Vercruysse J., Saliez A., Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007, 83:783.
24. Suarez-Alvarez B., Rodriguez R.M., Calvanese V., Blanco-Gelaz M.A., Suhr S.T., Ortega F., et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One 2010, 5:e10192.
25. Martins I., Deshayes F., Baton F., Forget A., Ciechomska I., Sylla K., et al. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Eur J Immunol 2007, 37:788.
26. Sassoli C., Pini A., Mazzanti B., Quercioli F., Nistri S., Saccardi R., et al. Mesenchymal stromal cells affect cardiomyocyte growth through juxtacrine Notch-1/Jagged-1 signaling and paracrine mechanisms: clues for cardiac regeneration. J Mol Cell Cardiol 2011, 51:399.
27. Nakano N., Nishiyama C., Yagita H., Koyanagi A., Ogawa H., Okumura K. Notch1-mediated signaling induces MHC class II expression through activation of class II transactivator promoter III in mast cells. J Biol Chem 2011, 286:12042.
28. Gebler A., Zabel O., Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2011, 18:128.
29. D'Orsogna L.J., van Besouw N.M., van der Meer-Prins E.M., van der Pol P., Franke-van Dijk M., Zoet Y.M., et al. Vaccine-induced allo-HLA-reactive memory T cells in a kidney transplantation candidate. Transplantation 2011, 91:645.
30. D'Orsogna L.J., Roelen D.L., van der Meer-Prins E.M., van der Pol P., Franke-van Dijk M.E., Eikmans M., et al. Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells. Transplantation 2011, 91:494.
31. D'Orsogna L.J., Roelen D.L., Doxiadis I.I., Claas F.H. TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition. Immunogenetics 2012, 64:77.
32. Campbell P.M., Salam A., Ryan E.A., Senior P., Paty B.W., Bigam D., et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007, 7:1242.
33. Kessler L., Parissiadis A., Bayle F., Moreau F., Pinget M., Froelich N., et al. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009, 9:1961.
34. Krystkowiak P., Gaura V., Labalette M., Rialland A., Remy P., Peschanski M., et al. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS One 2007, 2:e166.
35. Campbell P.M., Senior P.A., Salam A., Labranche K., Bigam D.L., Kneteman N.M., et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007, 7:2311.
36. Vaithilingam V., Tuch B.E. Islet transplantation and encapsulation: an update on recent developments. Rev Diabet Stud 2011, 8:51.
37. Hughes R.D., Mitry R.R., Dhawan A. Current Status of Hepatocyte Transplantation. Transplantation 2012, 93:342.
38. Gallina P., Paganini M., Lombardini L., Saccardi R., Marini M., De Cristofaro M.T., et al. Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Exp Neurol 2008, 213:241.
39. Gallina P., Paganini M., Lombardini L., Mascalchi M., Porfirio B., Gadda D., et al. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol 2010, 222:30.
40. Schu S., Nosov M., O'Flynn L., Shaw G., Treacy O., Barry F., et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2011, 1582-4934:01509. (Epub ahead of print).
41. Badillo A.T., Beggs K.J., Javazon E.H., Tebbets J.C., Flake A.W. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant 2011, 13:412.
42. Cho P.S., Messina D.J., Hirsh E.L., Chi N., Goldman S.N., Lo D.P., et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008, 111:430.
43. Deuse T., Seifert M., Phillips N., Fire A., Tyan D., Kay M., et al. Immunobiology of naive and genetically modified HLA-class-I-knockdown human embryonic stem cells. J Cell Sci 2011, 124:3029.
44. Terasaki P.I., Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005, 17:541.
45. Halloran P.F., de Freitas D.G., Einecke G., Famulski K.S., Hidalgo L.G., Menge L.M., et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010, 10:2223.
46. Sellares J., de Freitas D.G., Mengel M., Reeve J., Einecke G., Sis B., et al. Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence. Am J Transplant 2012, 12:388.
47. Gloor J., Cosio F., Lager D.J., Stegall M.D. The Spectrum of Antibody-Mediated Renal Allograft Injury: Implications for Treatment. Am J Transplant 2008, 8:1367.
48. Wehner J., Morrell C.N., Reynolds T., Rodriguez E.R., Baldwin W.M. Antibody and complement in transplant vasculopathy. Circ Res 2007, 100:191.
49. Lynch R.J., Platt J.L. Accommodation in renal transplantation: unanswered questions. Curr Opin Organ Transplant 2010, 15:481.
50. Beggs K.J., Lyubimov A., Borneman J.N., Bartholomew A., Moseley A., Dodds R., et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 2006, 15:711.
51. Blin G., Nury D., Stefanovic S., Neri T., Guillevic O., Brinon B., et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010, 120:1125.
52. Cho H.J., Lee N., Lee J.Y., Choi Y.J., Ii M., Wecker A., et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 2007, 204:3257.
53. Tseng H.C., Arasteh A., Paranjpe A., Teruel A., Yang W., Behel A., et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 2010, 5:e11590.
54. Frenzel L.P., Abdullah Z., Kriegeskorte A.K., Dieterich R., Lange N., Busch D.H., et al. Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. Stem Cells 2009, 27:307.
55. Koch C.A., Jordan C.E., Platt J.L. Complement-dependent control of teratoma formation by embryonic stem cells. J Immunol 2006, 177:4803.
56. Doisne J.M., Castaigne J.G., Deruyffelaere C., Dieu-Nosjean M.C., Chamot C., Alcaide-Loridan C., et al. The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes. Mol Immunol 2008, 45:709.
57. Leveille C., Castaigne J.G., Charron D., Al-Daccak R. MHC class II isotype-specific signaling complex on human B cells. Eur J Immunol 2002, 32:2282.
58. Zhang X., Rozengurt E., Reed E.F. HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci Signal 2010, 3:ra85.
59. Aoudjit F., Guo W., Gagnon-Houde J.V., Castaigne J.G., Alcaide-Loridan C., Charron D., et al. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp Cell Res 2004, 299:79.
60. Bertho N., Blancheteau V.M., Setterblad N., Laupeze B., Lord J.M., Drenou B., et al. MHC class II-mediated apoptosis of mature dendritic cells proceeds by activation of the protein kinase C-delta isoenzyme. Int Immunol 2002, 14:935.
61. Mehindate K., Al-Daccak R., Dayer J.M., Kennedy B.P., Kris C., Borgea P., et al. Superantigen-induced collagenase gene expression in human IFN-gamma-treated fibroblast-like synoviocytes involves prostaglandin E2. Evidence for a role of cyclooxygenase-2 and cytosolic phospholipase A2. J Immunol 1995, 155:3570.
62. Barbieri G., Rimini E., Costa M.A. Effects of human leukocyte antigen (HLA)-DR engagement on melanoma cells. Int J Oncol 2011, 38:1589.
63. Jindra P.T., Jin Y.P., Rozengurt E., Reed E.F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008, 180:2357.
64. Lepin E.J., Zhang Q., Zhang X., Jindra P.T., Hong L.S., Ayele P., et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006, 6:1560.
65. Jaramillo A., Smith C.R., Maruyama T., Zhang L., Patterson G.A., Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003, 64:521.
66. Malliaras K., Kreke M., Marban E. The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther 2011, 90:532.
67. Leri A., Kajstura J., Anversa P. Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. Circ Res 2011, 109:941.
68. Malliaras K., Li T.S., Luthringer D., Terrovitis J., Cheng K., Chakravarty T., et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012, 125:100.
69. Jin Y.P., Singh R.P., Du Z.Y., Rajasekaran A.K., Rozengurt E., Reed E.F. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol 2002, 168:5415.
70. Mehindate K., Al-Daccak R., Schal T.J., Mourad W. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone. J Biol Chem 1994, 269:32063.
71. Bieri M., Oroszlan M., Farkas A., Ligeti N., Bieri J., Mohacsi P. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol 2009, 41:2422.
72. Narayanan K., Jaramillo A., Phelan D.L., Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004, 34:2303.
73. Duquesnoy R.J., Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 2007, 68:12.
74. Dudkiewicz M., Malanowski P., Czerwin Ski J., Pawlowski K. An approach to predicting hematopoietic stem cell transplantation outcome using HLA-mismatch information mapped on protein structure data. Biol Blood Marrow Transplant 2009, 15:1014.
75. Gourraud P.A., Gilson L., Girard M., Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic " haplobank" of induced pluripotent stem cell lines. Stem Cells 2012, 30:180.
76. Gebel H.M., Bray R.A. Approaches for transplanting the sensitized patient: biology versus pharmacology. Nephrol Dial Transplant 2008.
77. Cecka J.M. Current methodologies for detecting sensitization to HLA antigens. Curr Opin Organ Transplant 2011, 16:398.
78. Taylor C.J., Kosmoliaptsis V., Summers D.M., Bradley J.A. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009, 70:563.
79. Lefaucheur C., Loupy A., Hill G.S., Andrade J., Nochy D., Antoine C., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 21:1398.
80. Bradley J.A., Baldwin W.M., Bingaman A., Ellenrieder C., Gebel H.M., Glotz D., et al. Antibody-mediated rejection-an ounce of prevention is worth a pound of cure. Am J Transplant 2011, 11:1131.
81. Claas F.H., Witvliet M.D., Duquesnoy R.J., Persijn G.G., Doxiadis I.I. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004, 78:190.
82. Lefaucheur C., Antoine C., Suberbielle C., Glotz D. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011, 11:1592.